Fig. 2: The verification of potential protein biomarkers for EOCs in plasma samples.

A Proteomic profiling for plasma samples and the verification of potential protein biomarkers upregulated along with the increased malignancy of ovarian tissues in plasma samples. N represents patient number, n represents sample number, # represents batch number, NA represents missing values. Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license (https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en). B The DEPs of plasma samples between primary HGSOC and non-carcinoma groups by two-sided unpaired Welch’s t est. P-values were adjusted for multiple comparisons using the B–H correction method. C The expression of the eight validated proteins in plasma samples between primary HGSOC (n = 134) and non-carcinoma (n = 34) groups. P-values were determined using a two-sided unpaired Welch’s t test and subsequently adjusted using the B–H correction method. The box in each group is constructed from the first to the third quartile, with a horizontal line indicating the median value. The whiskers extend from the box to represent the range of data within 1.5 times the interquartile range. D The total AUCs by five-fold cross-validation using each feature and eight-feature model. E The average value of Mean Decrease Accuracy among five-fold cross-validation when building the eight-feature model. F The total AUCs by five-fold cross-validation using two to eight features selected by importance ranking. Source data are provided as a Source Data file.